Valneva and Pfizer report further positive phase 2 data for Lyme disease vaccine candidate
4 February 2022Dose selection complete for planned Phase 3 trial, expected to be initiated in 3Q2022 Sub-analysis compared the immunogenicity of VLA15... View Article